The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Patent Protection - Rapid Blood Cell Separator

16 Mar 2011 07:00

RNS Number : 0188D
Akers Biosciences, Inc.
16 March 2011
 

Embargoed: 0700hrs, 16 March 2011

Akers Biosciences, Inc.

("ABI" or the "Company")

 

ABI Granted Patent Protection for Rapid Blood Cell Separator Technology

 

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, is pleased to announce that it has been granted patent protection in the United States, under patent 7,896,167 B2, for its novel blood cell separator technology (the "Technology"). The Technology forms a key element of the Company's PIFA POC test - the point-of-care extension of ABI's heparin platelet factor 4 rapid assay and has also been integrated into ABI's Lithium "Check" System. The Technology could also be used in many other diagnostic tests transforming them from use only in clinical laboratories to point-of-care.

 

ABI's Technology is for a novel composite which enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. Serum or plasma samples are extracted within minutes and are ready for immediate analysis by rapid assay devices, such as ABI's own products, delivering real-time results. By contrast, conventional methods of blood cell separation are labour-intensive and time consuming, typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialised equipment.

 

Dr Raymond F. Akers, Jr., Executive Chairman, commented:

 

"With an industry shift towards point-of-care testing, ABI is well positioned as a provider of rapid diagnostic solutions that encompass the totality of the testing process, from sample preparation to test result. We believe that the Technology provides a significant step forward in the development of point-of-care diagnostic tests which could benefit not only ABI's products but those of the wider point-of-care diagnostic community."

 

Enquiries:

 

Thomas A. Nicolette, President and CEO

Dr Raymond F. Akers, Jr., Executive Chairman

Tel. +1 856 848 8698

Antony Legge or Noelle Greenaway

Daniel Stewart & Company plc (Nomad and Broker)

Tel. +44 (0)20 7776 6550

 

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical product distributors to maximise product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFSFUIFFSESD
Date   Source Headline
4th Jun 20147:00 amRNSDistribution Agreement Signed
16th May 20147:00 amRNSAgreement to Market Rapid Tests in India
14th May 201412:00 pmRNSFirst Quarter Results
7th May 20147:00 amRNSInternational Distribution Agreement
30th Apr 20147:01 amRNSClinical Trials for PIFA PLUSS Chlamydia Assay
28th Mar 201411:00 amRNSFinal Results
27th Mar 201411:00 amRNSSenior Managerial Appointment
12th Mar 20145:12 pmRNSDirectorate Change
11th Mar 20144:30 pmRNSNASDAQ IPO Update
11th Mar 20144:29 pmRNSHolding(s) in Company
31st Jan 20145:30 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSDirector/PDMR Shareholding
31st Jan 20147:00 amRNSTotal Voting Rights
27th Jan 20142:46 pmRNSAppointment of Non-Executive Director
24th Jan 20147:30 amRNSRestoration - Akers Biosciences, Inc
23rd Jan 20146:10 pmRNSPricing of Offering & Recommencement of Trading
23rd Jan 20147:30 amRNSSuspension - Akers Biosciences, Inc.
23rd Jan 20147:30 amRNSTemporary Suspension
7th Jan 20145:27 pmRNSCorrection: SEC filings available on website
7th Jan 20144:54 pmRNSSEC filings available on Company's web site
2nd Jan 201410:37 amRNSHolding(s) in Company
31st Dec 201312:34 pmRNSCorrection: Total Voting Rights
31st Dec 20138:00 amRNSTotal Voting Rights
30th Dec 20137:00 amRNSIssue of Equity
23rd Dec 20137:00 amRNSPlacing of Shares
9th Dec 20137:00 amRNSProposed NASDAQ Listing
6th Dec 20137:00 amRNSDirector Dealing
5th Dec 20139:51 amRNSHolding(s) in Company
29th Nov 20134:00 pmRNSTotal Voting Rights
18th Nov 20137:00 amRNSShare Capital Consolidation
15th Nov 20132:37 pmRNSUnaudited results for nine months ended 30.09.2013
7th Nov 20134:55 pmRNSHolding(s) in Company
23rd Oct 20133:09 pmRNSHolding(s) in Company
17th Oct 20132:09 pmRNSHolding(s) in Company
17th Oct 20131:54 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results for Six Months Ended 30 June 2013
15th Aug 20138:55 amRNSHolding(s) in Company
8th Aug 20137:00 amRNSProposed NASDAQ Listing
23rd Jul 20137:00 amRNSDirector's Dealing
19th Jul 20137:00 amRNSTrading Statement
10th Jul 20139:51 amRNSHolding(s) in Company
1st Jul 20139:41 amRNSAppointment of Non-Executive Directors
26th Jun 20137:00 amRNSPreliminary Results for Year End 31 December 2012
14th Jun 201312:25 pmRNSHolding(s) in Company
13th Jun 20131:24 pmRNSExtension of Agreement & $1.6m Subscription
10th Apr 20137:00 amRNSTrading Update
27th Feb 20138:39 amRNSFinal Award of NF Mark
19th Feb 20137:00 amRNSTrading Update
20th Dec 20125:35 pmRNSResult of AGM
11th Dec 20127:00 amRNS3.5m unit Order for Breath Alcohol tubes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.